De Novo and Recurrent Tumors Post Organ Transplantation
Conditions
Interventions
De Novo and Recurrent Tumors Post Organ Transplantation:Does not involve
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Retrospective Study: Patients who underwent allogeneic renal transplantation at West China Hospital of Sichuan University between 2015 and 2023, aged over 18 and under 65 years, regardless of gender, will be included. Additionally, data will be collected on patients who developed de novo tumors post-renal transplantation between 2015 and 2023, along with a matched control cohort. Prospective Study: Patients who will undergo allogeneic renal transplantation from deceased donors at West China Hospital of Sichuan University between 2024 and 2026, aged between 18 and 65 years, will be prospectively enrolled.
Exclusion criteria
Exclusion criteria: 1 Recipients with a history of malignancy; 2 Kidney transplant recipients whose donor relatives have a history of malignancy; 3 Recipients with ABO blood type incompatibility; 4 Recipients with active hepatitis B or hepatitis C (positive HBV-DNA or HCV-RNA in blood).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient basic information;Test results;Imaging results;Pathology examination results;Medication Treatment Plan; | — |
Countries
China
Contacts
Public ContactLin Tao
West China Hospital of Sichuan University
Outcome results
None listed